Terms: = Kidney tumors AND IL2, IL-2, 3558, ENSG00000109471, P60568
1127 results:
1. A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.
Xu J; Zhang W; Tong J; Liu C; Zhang Q; Cao L; Yu J; Zhou A; Ma J
Cancer Immunol Immunother; 2024 Apr; 73(6):107. PubMed ID: 38642109
[TBL] [Abstract] [Full Text] [Related]
2. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract] [Full Text] [Related]
3. Risk assessment of cancer patients based on HLA-I alleles, neobinders and expression of cytokines.
Dhall A; Patiyal S; Kaur H; Raghava GPS
Comput Biol Med; 2023 Dec; 167():107594. PubMed ID: 37918263
[TBL] [Abstract] [Full Text] [Related]
4. Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P; Grandal B; Jochum F; Bihan K; Coussy F; Barraud S; Asselain B; Dumas E; Sebbag C; Hotton J; Spaggiari E; Pierga JY; Savarino R; Laas E; Spano JP; Reyal F; Hamy AS
JAMA Netw Open; 2023 Oct; 6(10):e2339934. PubMed ID: 37883083
[TBL] [Abstract] [Full Text] [Related]
5. Prognostic and predictive significance of GITR in metastatic renal cell carcinoma.
Balçık OY; Akın D; Ceylan GS; Demİr B; Aytaç A; Çulhacı N; Oktay E
Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7781-7792. PubMed ID: 37667956
[TBL] [Abstract] [Full Text] [Related]
6. Viral Vectors Expressing Interleukin 2 for Cancer Immunotherapy.
Wang H; Borlongan M; Hemminki A; Basnet S; Sah N; Kaufman HL; Rabkin SD; Saha D
Hum Gene Ther; 2023 Sep; 34(17-18):878-895. PubMed ID: 37578106
[TBL] [Abstract] [Full Text] [Related]
7. First-line ICIs in renal cell carcinoma.
Fiorentino V; Tralongo P; Larocca LM; Pizzimenti C; Martini M; Pierconti F
Hum Vaccin Immunother; 2023 Aug; 19(2):2225386. PubMed ID: 37395601
[TBL] [Abstract] [Full Text] [Related]
8. Rethinking Oncologic Treatment Strategies with Interleukin-2.
Ko B; Takebe N; Andrews O; Makena MR; Chen AP
Cells; 2023 May; 12(9):. PubMed ID: 37174716
[TBL] [Abstract] [Full Text] [Related]
9. A systematic review of interleukin-2-based immunotherapies in clinical trials for cancer and autoimmune diseases.
Raeber ME; Sahin D; Karakus U; Boyman O
EBioMedicine; 2023 Apr; 90():104539. PubMed ID: 37004361
[TBL] [Abstract] [Full Text] [Related]
10. CD25
Chen Z; Tong L; Neo SY; Li S; Gao J; Schlisio S; Lundqvist A
Oncoimmunology; 2023; 12(1):2175517. PubMed ID: 36970070
[TBL] [Abstract] [Full Text] [Related]
11. Organ Transplants From Deceased Donors With Primary Brain tumors and Risk of Cancer Transmission.
Greenhall GHB; Rous BA; Robb ML; Brown C; Hardman G; Hilton RM; Neuberger JM; Dark JH; Johnson RJ; Forsythe JLR; Tomlinson LA; Callaghan CJ; Watson CJE
JAMA Surg; 2023 May; 158(5):504-513. PubMed ID: 36947028
[TBL] [Abstract] [Full Text] [Related]
12. Exhausted intratumoral Vδ2
Rancan C; Arias-Badia M; Dogra P; Chen B; Aran D; Yang H; Luong D; Ilano A; Li J; Chang H; Kwek SS; Zhang L; Lanier LL; Meng MV; Farber DL; Fong L
Nat Immunol; 2023 Apr; 24(4):612-624. PubMed ID: 36928415
[TBL] [Abstract] [Full Text] [Related]
13. Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and il2: A Real-world Evidence Study of Patients with Advanced Renal Cancer.
Eisner JR; Beebe KD; Mayhew GM; Shibata Y; Guo Y; Farhangfar C; Farhangfar F; Uronis JM; Mooney J; Milburn MV; Foureau D; White RL; Amin A; Milla ME
Cancer Res Commun; 2022 Aug; 2(8):894-903. PubMed ID: 36923304
[TBL] [Abstract] [Full Text] [Related]
14. Copper Death Inducer, FDX1, as a Prognostic Biomarker Reshaping Tumor Immunity in Clear Cell Renal Cell Carcinoma.
Jiang A; Ye J; Zhou Y; Zhu B; Lu J; Ge S; Qu L; Xiao J; Wang L; Cai C
Cells; 2023 Jan; 12(3):. PubMed ID: 36766692
[TBL] [Abstract] [Full Text] [Related]
15. Synchronous or metachronous presentation of pancreatic neuroendocrine tumor versus secondary lesion to pancreas in patients affected by renal cell carcinoma. Systematic review.
Persano I; Parlagreco E; La Salvia A; Audisio M; Volante M; Buttigliero C; Scagliotti GV; Brizzi MP
Semin Oncol; 2022 Dec; 49(6):476-481. PubMed ID: 36759234
[TBL] [Abstract] [Full Text] [Related]
16. Teaching an old dog new tricks: re-engineering il-2 for immuno-oncology applications.
Sznol M; Rizvi N
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609489
[TBL] [Abstract] [Full Text] [Related]
17. Pyroptosis relates to tumor microenvironment remodeling and prognosis: A pan-cancer perspective.
Khan M; Ai M; Du K; Song J; Wang B; Lin J; Ren A; Chen C; Huang Z; Qiu W; Zhang J; Tian Y; Yuan Y
Front Immunol; 2022; 13():1062225. PubMed ID: 36605187
[TBL] [Abstract] [Full Text] [Related]
18. Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.
Vaishampayan UN; Thakur A; Chen W; Deol A; Patel M; Dobson K; Dickow B; Schalk D; Schienschang A; Whitaker S; Polend A; Fontana JA; Heath EI; Lum LG
Clin Cancer Res; 2023 Jan; 29(1):122-133. PubMed ID: 36255393
[TBL] [Abstract] [Full Text] [Related]
19. Next Wave of Targets in the Treatment of Advanced Renal Cell Carcinoma.
Cardenas LM; Deluce JE; Khan S; Gulam O; Maleki Vareki S; Fernandes R; Lalani AA
Curr Oncol; 2022 Jul; 29(8):5426-5441. PubMed ID: 36005167
[TBL] [Abstract] [Full Text] [Related]
20. Facts and Hopes for Immunotherapy in Renal Cell Carcinoma.
Yao C; Zhang T; Wu T; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(23):5013-5020. PubMed ID: 35819272
[TBL] [Abstract] [Full Text] [Related]
[Next]
